I-MAB Rebrands as NovaBridge Biosciences, Trading to Commence on October 30, 2025, Featuring New Brand and Logo to Highlight Strategic Shift to a Global Biotech Platform

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Oct 29 2025

0mins

Source: Globenewswire

Corporate Rebranding: I-Mab has officially changed its name to NovaBridge Biosciences, reflecting its strategic transformation into a global biotech platform aimed at enhancing access to innovative medicines. The new name and ticker symbol "NBP" will be effective on Nasdaq starting October 30, 2025.
Strategic Growth Plans: The company plans to pursue a dual listing on both Nasdaq and the Hong Kong Stock Exchange (HKEX) to broaden its investor base and enhance trading liquidity, while also forming a new subsidiary, Visara, to focus on developing specialized therapeutics.
Pipeline Development: NovaBridge's key assets include givastomig, a bispecific antibody for gastric cancer, and VIS-101, a bifunctional biologic targeting retinal diseases. Both are advancing through clinical trials, with significant milestones expected in the near future.
Business Model: The company employs a "hub-and-spoke" model to manage risk and create value through specialized subsidiaries, allowing for focused development of high-potential drug candidates in collaboration with leading innovators.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.